Good Neighbor Pharmacy, KaBOOM! and the Community YMCA design, build dream play space for children
RED BANK, N.J. — In less than eight hours, a play space was built at the Community YMCA’s Family Health and Wellness Center with the help of more than 200 volunteers from the Community YMCA, Good Neighbor Pharmacy and non profit KaBOOM!, the companies announced Monday. The new playground — which was made possible by funds donated by Good Neighbor Pharmacy and matched by its parent company, AmerisourceBergen — will serve hundreds of children in the community for years to come.
“The Community YMCA is truly grateful to KaBOOM! and Good Neighbor Pharmacy for their generosity and commitment to ensuring that all children have a safe place to play,” stated the Community YMCA president and CEO Rhonda Anderson. “We thank them and the many hardworking volunteers and local businesses who supported this project. Together, we are making a lasting impact for children in our community.”
Planning for the playground began at a design day event held on Sept. 3, where local children and community leaders met with organizers from KaBOOM! and Good Neighbor Pharmacy to design their dream playground. The children’s drawings were then used to create the final playground design.
“Good Neighbor Pharmacy is thrilled to have the opportunity to give back to local communities like Red Bank through our partnership with KaBOOM!,” stated AJ Caffentzis, SVP sales and marketing, at AmerisourceBergen. “We are committed to the health and well-being of our customers, employees and communities. Our Good Neighbor Pharmacy members, in particular, remain cornerstones of their respective communities, working to improve patient access and patient health in local neighborhoods across the country. We view our partnership with KaBOOM! as an extension of our commitment to local communities.”
The playground is the first of five that will be built together by KaBOOM! and Good Neighbor Pharmacy, the companies noted.
UCB seeks approval for Vimpat as stand-alone therapy in adults
ATLANTA — Drug maker UCB is seeking approval for one of its drugs as a stand-alone therapy for epilepsy.
The company said Monday that the Food and Drug Administration had accepted its regulatory approval application for Vimpat (lacosamide) for adult epilepsy patients with partial-onset seizures. The drug is already approved as an add-on therapy for partial-onset seizures in patients aged 17 and older.
"UCB has a strong heritage in epilepsy," UCB chief medical officer and EVP Iris Loew-Friedrich said. "The US filing for lacosamide in monotherapy is another step forward for people living with epilepsy."
Mylan files for approval of generic gout drug
PITTSBURGH — Mylan expects to be the first to market with a generic version of a drug for treating patients with gout, the company said Friday, though its filing has triggered a lawsuit from the makers of the branded version.
Mylan has filed with the Food and Drug Administration for approval of a generic version of Uloric (febuxostat) tablets in the 40-mg and 80-mg strengths, used for chronic treatment of hyperuricemia in patients with gout. Teijin owns the trademark for the drug and licenses it to Takeda, and both companies responded to the filing with a patent-infringement suit against Mylan in the U.S. District Court for the District of Delaware. The lawsuit was filed under the Hatch-Waxman Act of 1984 and places a stay of FDA approval on the generic drug for 30 months, or until the companies settle.
Uloric had sales of about $260.7 million during the 12-month period that ended in June, according to IMS Health. As the first company to win approval for a generic version of the drug, Mylan would have 180 days in which to compete exclusively against Teijin and Takeda.